Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 389

1.

Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management.

Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD.

Circulation. 2012 Jan 3;125(1):113-22. doi: 10.1161/CIRCULATIONAHA.111.026591.

2.

Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).

Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD.

Circulation. 2010 Jul 13;122(2):164-72. doi: 10.1161/CIRCULATIONAHA.109.898122.

3.

Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry).

Barst RJ, Ivy DD, Foreman AJ, McGoon MD, Rosenzweig EB.

Am J Cardiol. 2014 Jan 1;113(1):147-55. doi: 10.1016/j.amjcard.2013.09.032.

PMID:
24176071
5.
6.

Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry.

Barst RJ, Chung L, Zamanian RT, Turner M, McGoon MD.

Chest. 2013 Jul;144(1):160-8. doi: 10.1378/chest.12-2417.

PMID:
23429998
7.

Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival.

Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, Gressin V, Guillevin L, Clerson P, Simonneau G, Hachulla E.

Arthritis Rheum. 2011 Nov;63(11):3522-30. doi: 10.1002/art.30541.

8.

Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).

Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, Hill NS, Farber HW.

Circulation. 2015 Dec 22;132(25):2403-11. doi: 10.1161/CIRCULATIONAHA.115.018435.

9.

Portopulmonary hypertension: a report from the US-based REVEAL Registry.

Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB, McGoon MD.

Chest. 2012 Apr;141(4):906-15. doi: 10.1378/chest.11-0160.

PMID:
21778257
10.

Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.

Benza RL, Gomberg-Maitland M, Naeije R, Arneson CP, Lang IM.

J Heart Lung Transplant. 2011 Sep;30(9):982-9. doi: 10.1016/j.healun.2011.03.011.

PMID:
21531577
11.

Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry.

Farber HW, Miller DP, Meltzer LA, McGoon MD.

J Heart Lung Transplant. 2013 Nov;32(11):1114-22. doi: 10.1016/j.healun.2013.08.010.

PMID:
24035189
12.

Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria.

Douwes JM, van Loon RL, Hoendermis ES, Vonk-Noordegraaf A, Roofthooft MT, Talsma MD, Hillege HL, Berger RM.

Eur Heart J. 2011 Dec;32(24):3137-46. doi: 10.1093/eurheartj/ehr282.

13.
14.

An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.

Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD.

Chest. 2012 Aug;142(2):448-56.

PMID:
22281797
15.

Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension.

Douwes JM, Roofthooft MT, Bartelds B, Talsma MD, Hillege HL, Berger RM.

Int J Cardiol. 2013 Sep 30;168(2):1370-7. doi: 10.1016/j.ijcard.2012.12.080.

16.

Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry.

Chung L, Farber HW, Benza R, Miller DP, Parsons L, Hassoun PM, McGoon M, Nicolls MR, Zamanian RT.

Chest. 2014 Dec;146(6):1494-504. doi: 10.1378/chest.13-3014.

17.

Five-Year outcomes of patients enrolled in the REVEAL Registry.

Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, Romero AJ, Benton WW, Elliott CG, McGoon MD, Benza RL.

Chest. 2015 Oct;148(4):1043-54. doi: 10.1378/chest.15-0300.

18.
19.

Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis.

Poms AD, Turner M, Farber HW, Meltzer LA, McGoon MD.

Chest. 2013 Jul;144(1):169-76. doi: 10.1378/chest.11-3241.

PMID:
23348820
20.

Prevalence and impact of coronary artery disease in patients with pulmonary arterial hypertension.

Shimony A, Eisenberg MJ, Rudski LG, Schlesinger R, Afilalo J, Joyal D, Dragatakis L, Hirsch A, Boutet K, Fox BD, Langleben D.

Am J Cardiol. 2011 Aug 1;108(3):460-4. doi: 10.1016/j.amjcard.2011.03.066.

PMID:
21600533
Items per page

Supplemental Content

Support Center